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PLERIXAFOR USE IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT
CANDIDATES AT HIGH RISK FOR MOBILIZATION FAILURE
Shapiro, J.1, Perkins, J.2, Bookout, R.1, Ayala, E.2, Fernandez, H.2,
Janssen, W.2, Anasetti, C.2 1H. Lee Moffitt Cancer Center, Tampa,
FL; 2H. Lee Moffitt Cancer Center, Tampa, FL
Practice guidelines were developed at our institution to optimize
CD34 cell mobilization for autologous hematopoietic cell transplant.
We defined patients (pts) at high risk for mobilization failure and eli-
gible to receive G-CSF and plerixafor if they met any of the following
criteria: 1) received3ormore lines of prior chemotherapy; 2) received2
ormore lines of prior chemotherapy plus a radioimmunoconjugate; 3)
received 2 or more lines of prior chemotherapy plus radiation therapy
(XRT) to extensive fields; 4) received 4 ormore cycles of hyper-CVAD
or4ormore cycles of lenalidomide; or 5) hypocellular bonemarrow (\
25% cellularity). From 1/09-11/09, 30 consecutive high-risk pts re-
ceived G-CSF and plerixafor as primary mobilization therapy. All pts
received 4 doses of G-CSF (10 mcg/kg/d) and on the evening of the
4thday (at approximately7pm), they receivedG-CSF followedbypler-
ixafor 0.24 mg/kg. 6 pts were dosed at 0.16 mg/kg due to reduced cre-
atinine clearance. Apheresiswas started themorning after the first dose
of plerixafor. G-CSF, plerixafor, and apheresis were continued until at
least 2 or 4  10E6 CD341 cells/kg were collected, depending on
whether a single or a tandem transplant was planned. The median
age of the patients was 62 (range 33-71) years. Diagnoses includemul-
tiple myeloma (22), non-Hodgkin’s lymphoma (7) andHodgkin’s dis-
ease (1). Pts met the following high risk criteria: 3 or more lines of
chemotherapy (9 pts); 2 or more lines of chemotherapy plus XRT (2
pts); 4 ormore cycles of hyper-CVAD(4 pts); 4 ormore cycles of leno-
lidomide (18 pts); hypocellular bone marrow (6 pts). 7 pts had more
than 1 high risk feature. The median number (range) of G-CSF doses
were 4 (4-7), plerixafor doses 1 (1-3) and aphereses, 1 (1-3). The num-
ber of pts collectingat least 210E6CD341 cells (cumulative)with1,
2, and3 aphereseswere 23 (77%), 26 (87%), and28 (93%).Themedian
(range)of the numberofCD341 cells/kg collectedwith1 apheresis for
all pts was 4.23 (0.1-24.82). 4 pts were not transplanted: 2 due to an in-
ability to collect and 2 for other reasons. Of those 26 pts transplanted,
themedian time to absolute neutrophil count. 500/uLwas 12 (range
10-13) days andplatelet count. 20,000/uL (untransfused)was 17days
(range10-42)post-transplant.Weconclude thatplerixafor isbeneficial
in pts who are at high risk formobilization failure with 93%of patients
mobilizing adequate numbers of CD341 cells for transplant.145
EOSINOPHILIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION:
ANALYSIS OF FREQUENCY AND PROGNOSIS
Miyazaki, Y.1, Nawa, Y.2, Kohashi, S.2, Nakase, K.2, Hara, M.2 1Ehime
University Graduate School of Medicine, Toon, Ehime, Japan; 2Ehime
Prefectural Central Hospital, Matsuyama, Ehime, Japan
Introduction: The patients with eosinophilia after allogeneic stem
cell transplantation (allo-SCT) have often been reported to have
much longer overall survival and progression free survival than with-Table 1.
Diagnosis Previous Chemo
Plerixa
Dose
1 MM CTD , VELCADE 0.24 MG
2 NHL ABVD 0.24 MG
3 MM RDC, REVLIMID 0.24 MG
4 MM CTD, VELCADE 0.24 MG
5 HD ABVD, RADIOTHERAPY, ICE 0.24 MG
6 NEUROBLASTOMA TEMOZOLIDE, MIBG (RADIO
IODINATED TREATMENT
0.24 MG
7 MM CTD 0.24 MG
8 MM VELCADE + DEXAMETHASONE, REVLIMID 0.24 MG
9 HD ABVD, GEM-P 0.24 MG
10 MM CTD, VELCADE 0.24 MG
11 MM CTD, DEXAMETHASONE, RADIOTHERAPY 0.24 MGout eosinophilia. However, eosinophilia after autologous stem cell
transplantation (auto-SCT) has not been reported well. In this study,
we retrospectively analyzed the frequency of eosinophilia and the
prognosis of patients with eosinophilia after auto-SCT.
Patients andMethods: Between January 2006 andDecember 2009,
35 patients (18 multiple myeloma and 17 nonHodgkin’s lymphoma)
experienced autologous peripheral blood stem cell transplantation at
the Ehime Prefectural Central Hospital were analyzed. Eosinophilia
was defined according to the following criteria: (1) The count of
eosinocyte in the peripheral blood was over 500 cells per micro liter
after transplantation, (2) There was little relation to the drug-related
allergic reaction.
Results: The median observation time was 480 days (39-1497).
Fourteen of 35 patients (40%) had eosinophilia. The median onset
time was day 39.5 (range, day 22-116) and the duration of eosino-
philia was less than one month in most cases. On univariate analysis
between the group with eosinophilia and without eosinophilia, there
were no significant differences regarding age (p 5 0.625), time to
engraftment (p 5 0.448), sex (p 5 0.888) and CD341 cell dose
(p5 0.987). Kaplan-Meier method demonstrated that 2-year overall
survival and 2-year progression free survival were similar between
two groups (70.7% vs 48.8%; p 5 0.879, 51.6% vs 25.1%; p 5
0.569, respectively).
Conclusions: The frequency of eosinophilia after auto-SCT is
unexpectedly high. However, the duration of eosinophilia after
auto-SCT is much shorter than after allo-SCT and the relationship
between prognosis and eosinophilia may be little.146
IS IT MAGIC?
Vieira, S., Monroe, D. The Trustees of London Clinic, London, United
Kingdom
Introduction: Plerixafor (MOZOBIL) is an antagonist of alpha-
chemokine receptor CXCR and one of the new additions to the
Haematology discipline, it is a haematopoietic stem cell mobilizer.
Plerixafor is indicated in combination with Granulocyte Colony
Sitimulating Factor (GCSF) for Peripheral Blood Stem Cell
(PBSC) collections in Multiple Myeloma (MM) and Lymphoma
patient group with a poor mobilisation history.
Method: At The London Clinic, 12 patients received Plerixafor for
PBSC colection between May 2009 and September 2010. All patients
met the criteria prior to treatment (WhiteBloodCount. 2.5 109/L,
Absolute Neutrophil Count . 1.5  109/L, Platelet . 85  109/L,
Serum Creatinine \1.5 mg/dL, Aspartate transaminase (AST),
Alanine Transaminase (ALT), Bilirubin\2ULNwith no evidence
of Hepatitis B and C. Patient demographic data is shown in Table 1.
Two patients had an underlying documentedmedical problem (corto-
chondritis and glaucoma).
Results: Nine of the patients were diagnosed with MM, one with
Non-Hodgkin’s Lymphoma (NHL), one with Hodgkin’s Disease
and one with Neuroblastoma. All patients received four consecutive
days of GCSF 10 mg/kg prior to Plerixafor. Plerixafor was given 10
hours before the PBSC collection and GCSF was repeated in thefor GCSF
Dose
PBSC 1 CD34+
Cells/KG
Recipient Weight
PBSC2 CD34+
Cells/KG
Recipient Weight
PBSC 3 CD34+
Cells/KG
Recipient Weight
/KG 10 m/KG 7.39 X X
/KG 10 m/KG 21.79 X X
/KG 10 m/KG 4.62 X X
/KG 10 m/KG 2.03 X X
/KG 10 m/KG 1.16 1.08 0.42
/KG 10 m/KG 0.47 1.62 0.43
/KG 10 m/KG 2.55 5.48 X
/KG 10 m/KG 15.16 X X
/KG 10 m/KG 21.79 X X
/KG 10 m/KG 1.52 3.74 X
/KG 10 m/KG 0.64 1.50 1.34
